Title
Depressive symptoms in asymptomatic stage B heart failure with Type II diabetic mellitus.

Permalink
https://escholarship.org/uc/item/8pc5s6kt

Journal
Clinical cardiology, 42(6)

ISSN
0160-9289

Authors
Mills, Paul J
Taub, Pam R
Lunde, Ottar
et al.

Publication Date
2019-06-01

DOI
10.1002/clc.23187

Peer reviewed
Depressive symptoms in asymptomatic stage B heart failure with Type II diabetic mellitus

Paul J. Mills | Pam R. Taub | Ottar Lunde | Meredith A. Pung | Kathleen Wilson | Christopher Pruitt | Thomas Rutledge | Alan Maisel | Barry H. Greenberg

1Department of Family Medicine and Public Health, University of California San Diego, San Diego, California
2Department of Medicine, University of California San Diego, San Diego, California
3Department of Psychiatry, University of California San Diego, San Diego, California
4Division of Cardiology, San Diego VA Health Care System, San Diego, California

Correspondence
Paul J. Mills, PhD, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA 92093-0725.
Email: pmills@ucsd.edu

Funding information
NIH NCATS, Grant/Award Numbers: UL1TR001442, UL1TR000100; NIH NHLBI, Grant/Award Numbers: HL136407, H-096784, HL073355; National Institutes of Health

Abstract
Background: The presence of concomitant Type II diabetic mellitus (T2DM) and depressive symptoms adversely affects individuals with symptomatic heart failure (HF).

Hypothesis: In presymptomatic stage B HF, this study hypothesized the presence of greater inflammation and depressive symptoms in T2DM as compared to non-T2DM Stage B patients.

Methods: This cross-sectional study examined clinical parameters, inflammatory biomarkers, and depressive symptoms in 349 T2DM and non-T2DM men with asymptomatic stage B HF (mean age 66.4 years ±10.1; range 30-91).

Results: Fewer diabetic HF patients had left ventricular (LV) systolic dysfunction (P < .05) although more had LV diastolic dysfunction (P < .001). A higher percentage of T2DM HF patients were taking ACE-inhibitors, beta-blockers, calcium channel blockers, statins, and diuretics (P values < .05). T2DM HF patients had higher circulating levels of interleukin-6 (IL-6) (P < .01), tumor necrosis factor-alpha (P < .01), and soluble ST2 (sST2) (P < .01) and reported more somatic/affective depressive symptoms (Beck Depression Inventory II) (P < .05) but not cognitive/affective depressive symptoms (P = .20). Among all patients, in a multiple regression analysis predicting presence of somatic/affective depressive symptoms, sST2 (P = .026), IL-6 (P = .010), B-type natriuretic peptide (P = .016), and sleep (Pittsburgh Sleep Quality Index [P < .001]) were significant predictors (overall model F = 15.39, P < .001, adjusted R² = .207).

Conclusions: Somatic/affective but not cognitive/affective depressive symptoms are elevated in asymptomatic HF patients with T2DM patients. Linkages with elevated inflammatory and cardiac relevant biomarkers suggest shared pathophysiological mechanisms among T2DM HF patients with somatic depression, and these conditions are responsive to routine interventions, including behavioral. Copyright © 2019 John Wiley & Sons, Ltd.

KEYWORDS
depressive symptoms, heart failure, inflammation, T2DM
1 | INTRODUCTION

The American College of Cardiology/American Heart Association (ACC/AHA) heart failure (HF) staging system denotes four unique stages that emphasize both the evolution and the progression of chronic HF. One of the major goals of the system is to identify individuals at early stages of the disease with the hope that early implementation of therapeutic interventions might ultimately reduce morbidity and mortality. Stage B consists of patients who have developed structural or functional changes but who have never shown signs or symptoms of HF (eg, previous myocardial infarction, asymptomatic valvular disease, left ventricular hypertrophy, reduced ejection fraction). Progression from asymptomatic stage B to symptomatic stage C HF is associated with a 5-fold increase in premature mortality risk.

Like HF, Type II diabetic mellitus (T2DM) is a significant health problem, with rates expected to increase an estimated 25% over the next 7 years. T2DM is a significant comorbidity because, along with hypertension and obesity, it represents an independent risk factor for the development of HF. Like HF, T2DM is associated with chronic inflammation. Among symptomatic HF patients, presence of T2DM predicts morbidity and mortality.

Major depression is common in cardiovascular diseases and associated with poor medical outcomes. In symptomatic HF, studies have substantiated linkages between depression and inflammatory processes. In T2DM, a history of depression is associated with a higher rate of microvascular complications and higher HbA1c. Depression in T2DM independently and incrementally predicts incident HF.

In addition to major depression, depressive symptoms are also elevated in both HF and T2DM. Screening for depression symptoms can be routinely accomplished using standardized questionnaires such as the Beck Depression Inventory II (BDI-II). Several studies underscore the importance of differentiating the type of depressive symptoms the patient has, whether more somatic/affective or cognitive/affective depressive symptoms. For example, de Miranda Azevedo et al showed that in cardiovascular disease patients it is the somatic/affective depressive symptoms but not the cognitive/affective depressive symptoms that are related to poorer outcomes. Similarly, Delisle et al showed that following myocardial infarction the somatic/affective depressive symptoms contributed more to overall depression than the cognitive/affective depressive symptoms. We previously showed in symptomatic HF patients that a behavioral treatment for depressive symptoms was more successful in reducing somatic/affective rather than cognitive/affective depressive symptoms, which have been linked to worse prognosis in HF.

In contrast to the above research among patients with symptomatic HF (stage C), few studies have examined the comorbidity of depressive symptoms and T2DM in presymptomatic stage B HF. This paper sought to examine these relationships, and, in accordance with the studies described above which highlight the importance of differentiating somatic/affective vs cognitive/affective symptoms, examine potential clinical and inflammatory predictors of these phenomena in asymptomatic HF with and without T2DM.

2 | METHODS

Participants were 18 years or older with clinically stable AHA/ACC classification stage B HF with a diagnosis for at least 3 months. The sample consisted of 349 men. Patients were recruited from the University of California, San Diego (UCSD) Medical Center and the Veterans Affairs San Diego Healthcare System (VASDHS) Cardiology clinics. Individuals with a current cancer diagnosis or immune-related disorders including chronic infectious diseases (eg, HIV, hepatitis) and autoimmune and inflammatory disorders (eg, rheumatoid arthritis, multiple sclerosis, lupus, SLE, gout, sarcoidosis) were excluded, as were individuals with a body mass index (BMI) greater than 40, because of the known effects of these conditions on inflammatory biomarkers. The study was approved by the VASDHS and UCSD Human Subjects Institutional Review Boards. Written informed consent was obtained from all study participants.

Based on recommendations and cut-points from the American Society of Echocardiography guidelines, the presence of stage B HF was defined as structural or functional heart disease. Measurements were made by sonographers blinded to patient characteristics. Left ventricular ejection fraction (%LVEF) was assessed by echocardiography as part of the patient’s routine medical evaluation. Medication usage was obtained from the medical record. T2DM was deemed present when diagnosed by the research participant’s primary care physician via medical record abstraction. Upon presentation to the laboratory, a nonfasting blood draw was obtained using a 21- or 23-gauge butterfly needle. Patients performed a 6-minute walk test to assess functional capacity.

2.1 | Depressive symptom severity

The 21-item BDI-II assesses depressive symptoms, but does not provide a diagnosis of Major Depressive Disorder (MDD). BDI-II scores ≥13 indicate possible clinical depression (or at least minimal depressive symptomatology, or presence of depressive symptomatology.) If suspected of having actual clinical depression, patients were presented with a list of mental health treatment options, and their treating physician was notified. Approximately 20% of the cohort were taking antidepressants, which included tricyclic antidepressants, tetracyclic antidepressants, selective serotonin reuptake inhibitors, atypical antipsychotics, and selective serotonin and norepinephrine reuptake inhibitors. This study did not assess for presence of MDD but rather depressive symptoms only. The BDI provides a total score for depressive symptoms and two sub-scores: one, somatic/affective symptoms, and the other, cognitive/affective symptoms. As noted in the Introduction, prior studies demonstrate the value of differentiating somatic/affective vs cognitive/affective depressive symptoms in cardiac patients. BDI cognitive symptoms of depression include sadness, guilt, suicidality, and self-criticism. BDI somatic symptoms of depression include tiredness or fatigue, loss of interest, and changes in sleep, sex drive, and weight.
Sleep quality

The Pittsburgh Sleep Quality Index (PSQI) was used to independently assess sleep. Sleep quality is often disrupted in HF and associated with depressive symptoms, and common symptoms of somatic depression include poor sleep. The PSQI is widely used in sleep research and measures sleep disturbance and usual sleep habits. Its

### TABLE 1 Patient characteristics according to group (mean ± SD or percentage value)

|                          | T2DM (n = 116) | Non-T2DM (n = 233) | P values |
|--------------------------|----------------|-------------------|----------|
| Age (years)              | 66.34 (8.33)   | 66.45 (10.8)      | .921     |
| Body mass index (kg/m²)  | 32.1 (6.8)     | 29.2 (4.9)        | .000     |
| Percent overweight (BMI ≥25 to ≤29.9) | 25.8 | 37.3 | .044 |
| Percent obese (BMI ≥30)  | 63.7           | 40.8              | .000     |
| Waist-hip ratio          | 0.995 (0.065)  | 0.962 (0.062)     | .001     |
| Race (%)                 |                |                   | .296     |
| Asian                    | 8.9            | 3.0               |          |
| African-American         | 14.2           | 11.7              |          |
| Native Hawaiian/Pacific Islander | <1 | 1.7 |          |
| Caucasian                | 71.5           | 79.4              |          |
| Native-American          | <1             | <1                |          |
| More than one race       | 3.6            | 2.6               |          |
| Ethnicity (%)            |                |                   | .019     |
| Latino                   | 12.5           | 4.4               |          |
| Non-Latino               | 86.7           | 92.5              |          |
| Unknown/declined         | <1             | 3.1               |          |
| Systolic blood pressure (mm Hg) | 132.4 (18.5) | 132.6 (17.1) | .935 |
| Diastolic blood pressure (mm Hg) | 74.1 (12.8) | 76.4 (11.9) | .300 |
| Percent hypertension (≥140/90 mm Hg) | 36.2 | 32.1 | .437 |
| Heart rate (bpm)         | 68.3 (12.9)    | 64.0 (11.9)       | <0.01    |
| Left ventricular ejection fraction (%) | 65.0 (7.76) | 64.4 (9.47) | .437 |
| Percent patients with LV systolic dysfunction | 3.4 | 5.5 | <0.05 |
| Percent patients with LV diastolic dysfunction | 79 | 68 | .001 |
| Six-minute walk test (m) | 1029.3 (298)   | 1124.6 (302)      | <0.02    |
| Etiology: percent previous MI | 5.2 | 7.2 | .331 |
| Etiology: percent hypertension | 83.6 | 54.4 | .012 |
| Medications (% of patients using) | | | |
| ACE-blocking agents      | 51.8           | 37.9              | .017     |
| ARBs                     | 17.5           | 11.0              | .096     |
| Beta blockers            | 57.7           | 43.9              | .019     |
| Calcium channel blockers | 30.2           | 19.9              | .037     |
| Statin                   | 75.2           | 55.0              | .001     |
| Aspirin                  | 54.6           | 39.9              | .012     |
| Diuretics                | 31.4           | 20.3              | .027     |
| Warfarin                 | 13.3           | 14.0              | .822     |
| Digoxin                  | 3.6            | 1.8               | .316     |
| Antidepressants          | 20.2           | 19.4              | .711     |
| Sleep (PSQI total score) | 8.075 (4.20)   | 7.296 (4.09)      | .112     |
| BDI total                | 9.21 (7.64)    | 7.83 (6.91)       | .068     |
| BDI cognitive            | 4.88 (5.55)    | 4.09 (4.94)       | .179     |
| BDI somatic              | 4.55 (2.89)    | 3.82 (2.77)       | .039     |

Abbreviations: ACE, Angiotensin converting enzyme inhibitors; ARB, Angiotensin II receptor blockers; BDI, Beck Depression Inventory; BMI, body mass index; LV, left ventricular; PSQI, Pittsburgh Sleep Quality Index; T2DM, Type II diabetic mellitus.
internal reliability and construct validity are high, correlating well with measures of sleep quality and sleep problems.25

2.3 | Biomarkers

Considering linkages between inflammation and depressed mood in HF,8,9,26 we used commercial assays to assess the inflammatory biomarkers interleukin-6 (IL-6) and tumor necrosis factor-R1 (TNF-R1) (MSD, Rockville, Maryland). We also assessed C-reactive protein (MSD, Rockville, Maryland) and cardiac biomarkers B-type natriuretic peptide (BNP) immunoassay (Bayer, Tarrytown, New York) and soluble ST2 (sST2) (R&D Systems, Inc., Minneapolis, Minnesota). Whole blood was preserved with EDTA acid. Following centrifugation the plasma was stored at −80°C until assay. Intra- and inter-assay coefficients were <7%.

2.4 | Data analysis

Analytic approaches included chi-square, analysis of variance, and multiple linear regression. All tests were two-tailed. Prior to statistical analyses, data were tested for normality and homogeneity of variance using the Kolmogorov-Smirnov and Shapiro-Wilk normality tests. Results were considered statistically significant at the P < .05 level. Analyses were performed using SPSS (version 24.0) software packages (IBM, Armonk, New York).

3 | RESULTS

Table 1 presents the study variables according to T2DM diagnosis or non-T2DM. Overall, 116 of the 339 patients (34%) had T2DM. By definition, these patients had higher fasting glucose (P < .001) and HbA1c (P < .001) levels than non-T2DM patients. Twenty-two percent of diabetics were on insulin therapy. T2DM patients had higher BMI (P < .001), greater waist-hip ratio (P < .001), higher resting heart rate (P < .01), and a shorter 6-minute walk test (P < .02). More T2DM patients were obese (BMI ≥ 30.0) (P < .001) and overweight (BMI ≥ 25 to ≤ 29.9) (P < .05). LV diastolic dysfunction was more common in the T2DM patients (P < .001) while systolic dysfunction was less common (P < .05). Percent EF did not vary according to T2DM diagnosis (P = .622).

A higher percentage of T2DM patients were taking Angiotensin converting enzyme inhibitors (ACE)-inhibitors (P < .02), beta-blockers (P < .02), calcium channel blockers (P < .05), statins (P < .001), aspirin (P < .02), and diuretics (P < .02). T2DM patients had higher circulating levels of IL-6 (P < .01), TNF-R1 (P < .01), and sST2 (P < .01). BNP levels were not statistically significantly different according to group (Table 2).

T2DM patients reported more somatic/affective depressive symptoms (P < .04), but not cognitive depression symptoms (P = .179) nor total depressive symptoms (P = .068). Thirty-nine percent of T2DM patients scored ≥13 on the BDI vs. 29% of non-T2DM patients (P = .067). Approximately 20.2% of T2DM patients reported taking antidepressants vs. 19.4% of non-T2DM patients (P = .87).

### TABLE 2  Biomarkers according to group (mean ± SD)

|                | T2DM (n = 116) | Non-T2DM (n = 233) | P values |
|----------------|----------------|--------------------|----------|
| Glucose (mg/dL)| 141.2 (57)     | 99.6 (17.6)        | .001     |
| HbA1C (%)      | 6.77 (1.34)    | 5.58 (0.38)        | .001     |
| CRP (mg/L)     | 6.61 (11.9)    | 4.98 (7.64)        | .097     |
| IL-6 (pg/mL)   | 2.63 (2.38)    | 2.03 (1.79)        | .009     |
| TNF-R1 (pg/mL) | 1388.6 (793)   | 1173.2 (549)       | .007     |
| sST2 (ng/mL)   | 19.02 (8.30)   | 16.88 (7.89)       | .204     |
| BNP (pg/mL)    | 65.4 (91.7)    | 60.7 (67.0)        | .554     |

Abbreviations: BNP, B-type natriuretic peptide; CRP, C-reactive protein; IL-6, interleukin-6; sST2, soluble ST2; T2DM, Type II diabetic mellitus; TNF-R1, tumor necrosis factor-R1.

Given that T2DM patients reported more somatic/affective depressive symptoms, but not cognitive depression symptoms, a multiple regression analysis predicting somatic/affective symptoms was conducted across all patients with BDI-II somatic/affective scores as the dependent variable and relevant independent predictor variables entered in separate blocks as shown in Table 3. The significant outcome predictors included sST2 (P = .026), IL-6 (P = .010), BNP (P = .016), and sleep (P < .001) (model significance P < .001; adjusted $R^2 = .207$) (Table 3).

### TABLE 3  Regression analysis

**Dependent variable:** somatic/affective depressive symptoms

| Block 1: age, BMI, and T2DM diagnosis |
|--------------------------------------|
| Significant outcome predictors included: |
| sST2 ($\beta = .045$; $P = .026$) |
| IL-6 ($\beta = .223$; $P = .010$) |
| BNP ($\beta = .005$; $P = .016$) |
| Sleep ($\beta = .267$; $P < .001$) |
| **Overall model:** $P < .001$, adjusted $R^2 = .207$ |

Abbreviations: BMI, body mass index; BNP, B-type natriuretic peptide; CRP, C-reactive protein; IL-6, interleukin-6; LVEF, left ventricular ejection fraction; sST2, soluble ST2; T2DM, Type II diabetic mellitus; TNF-R1, tumor necrosis factor-R1.

4 | DISCUSSION

This study examined clinical, inflammatory, and depressive symptom characteristics in asymptomatic stage B HF patients with and without T2DM. T2DM stage B patients had more obesity and hypertension, and a greater incidence of LV diastolic dysfunction, which has been
previously observed in stage A HF patients and is associated with poorer prognosis.\textsuperscript{27} T2DM patients also had higher circulating levels of IL-6, TNF-R1, and sST2, of which IL-6 and sST2 were found to be predictors of somatic/affective depression, which was also elevated in the T2DM patients. While we did not have the ability to fully characterize the presence of metabolic syndrome, given the relatively high percentage of diabetes, hypertension, and obesity in this cohort, it is likely that a large percentage of the patients had metabolic syndrome.\textsuperscript{28}

In T2DM, the comorbidity of depressive symptoms and of major depression is associated with poorer clinical management and poorer outcomes than either alone\textsuperscript{29}; the same pattern is found for coincident depression and HF.\textsuperscript{7} We found that T2DM patients specifically had more somatic/affective depressive symptoms but not cognitive depression symptoms nor total depressive symptoms. Somatic/affective depressive symptoms include fatigue, loss of interest, and changes in sleep. Prior studies on depression in T2DM have not differentiated between somatic/affective vs cognitive/affective symptoms.\textsuperscript{10,30} Studies in non-T2DM populations, however, that have differentiated somatic/affective from cognitive/affective depression have found this assessment approach to be beneficial.\textsuperscript{15-17} Hwang et al. reported that worsening somatic/affective depressive symptoms but not cognitive/affective symptoms are independently associated with increased mortality of HF patients. Such findings suggest that routine and ongoing assessment of somatic/affective depressive symptoms in HF patients may help clinicians identify patients at increased risk for adverse outcomes.\textsuperscript{31} Relevant to asymptomatic stage B patients, following myocardial infarction, somatic/affective depressive symptoms contribute more to overall depression than the cognitive/affective depressive symptoms.\textsuperscript{16}

Mechanistically, we found that sST2, IL-6, BNP, and poor sleep quality were independent predictors of somatic/affective depression while BMI, type of cardiac dysfunction, and medications were not. Regarding IL-6, there is a large literature on the role of inflammatory processes in depression, including in HF, which point to neurohormonal and cytokine activation mechanisms linking these comorbidities.\textsuperscript{8,10,32} There is also a large literature on inflammation and fatigue that is relevant to these findings of increased somatic depressive symptoms.\textsuperscript{33}

Limitations of this observational study include the demographics of mostly white older men, thus limiting potential generalizability. In addition, we did not assess for presence of major depression, but rather we focused on depressive symptoms which have been shown in the literature to be highly predictive of poor clinical course.\textsuperscript{7}

It is important to note that a significant percentage of these patients had depressive symptoms: 39% of the T2DM patients and 29% of the non-T2DM patients. As noted above, depressive symptoms and depressed mood are significant predictors of morbidity and mortality in cardiac and noncardiac populations.\textsuperscript{7} Therapeutic lifestyle changes that target diet and exercise are known to positively influence depressed mood.\textsuperscript{34,35} We have previously shown that standard cardiac rehabilitation is effective in not only reducing mortality risk but also in reducing depression symptoms in HF,\textsuperscript{7} and that other forms of behavioral interventions favorably affect the somatic/affective but not the cognitive/affective depressive symptoms.\textsuperscript{17}

Given the elevated IL-6, TNF-R1, and sST2 levels in stage B HF patients with both T2DM and depressed mood, additional attention and interventions to forestall potential transition to symptomatic stage C HF may be warranted.\textsuperscript{36} The pathophysiology of stage B HF, combined with the presence of T2DM, might synergize to advance the likelihood of poorer outcomes. In addition to depressed mood, stress is a known link between depression and inflammation and metabolic syndrome and could in part account for our observations.\textsuperscript{33,37} Studies on approaches to stress reduction have also been shown to be helpful in improving depressed mood and inflammation.\textsuperscript{38}

Going forward, considering these findings, additional attention to assess depressive symptoms and presence of T2DM in stage B HF is warranted. Assessing depressive symptoms in the clinic using questionnaires such as the BDI or the Hospital Anxiety and Depression scale is relatively easy and low-cost and can provide insight into clinical outcomes.\textsuperscript{39,40}

ACKNOWLEDGMENT

This work was supported by grants HL073355, H-096784, HL136407, UL1TR000100, and UL1TR001442 from the National Institutes of Health.

CONFLICT OF INTEREST

Pam R. Taub is a consultant for Sanofi/Regeneron, Novo-Nordisk, Boehringer-Ingelheim, Janssen, Pfizer and Amgen. She is a stock holder of Cardero Therapeutics. All the other authors declare no potential conflict of interests.

ORCID

Paul J. Mills https://orcid.org/0000-0003-4263-7686

REFERENCES

1. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46(6):e1-82.

2. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett Jr JC, Rodeheffer RJ. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 2007;115(12):1563–1570.

3. Rowlley WR, Bezold C. Creating public awareness: state 2025 diabetes forecasts. Popul Health Manag 2012;15(4):194–200.

4. De Rosa S, Arcidiacono B, Chieffari E, Brunetti A, Indolfi C, Foti DP. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol (Lausanne) 2018;9:2.
5. Williams LJ, Nye BG, Wende AR. Diabetes-related cardiac dysfunction. Endocrinol Metab (Seoul) 2017;32(2):171–179.

6. Lopez-Candales A, Hernandez Burgos PM, Hernandez-Suarez DF, Harris D. Linking chronic inflammation with cardiovascular disease: from normal aging to the metabolic syndrome. J Nat Sci 2017;3(4).

7. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006;48(8):1527–1537.

8. Jimenez JA, Mills PJ. Neuroimmune mechanisms of depression in heart failure. Methods Mol Biol 2012;934:165–182.

9. Vaccarino V, Johnson BD, Sheps DS, Reis SE, Kelsey SF, Bittner V, Rutledge T, Shaw LJ, Sopko G, Bairey Merz CN, National Heart, Lung, and Blood Institute Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol 2007;50(21):2044–2050.

10. Levinger I, Selig S, Jerums G, Stewart A, Gaskin CJ, Hare DL. Depressed mood, glycaemic control and functional capacity in overweight/obese men with and without type 2 diabetes. Diabetol Metab Syndr 2012;4(1):46.

11. Wang Y, Yang H, Nolan M, Pathan F, Negishi K, Marwick TH. Association of depression with evolution of heart failure in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2018;17(1),19.

12. Jimenez JA, Redwine LL, Rutledge TR, Dimsdale JE, Pung MA, Ziegler MG, Greenberg BH, Mills PJ. Depression ratings and antidepressant use among outpatient heart failure patients: implications for the screening and treatment of depression. Int J Psychiatry Med 2012;44(4):315–334.

13. Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord 2012;142 suppl:58–21.

14. Tesio V, Marra S, Molinario S, Torta R, Gaia F, Castelli L. Screening of depression in cardiology: a study on 617 cardiovascular patients. J Cardiol 2017;245:49–51.

15. de Miranda Azevedo R, Roest AM, Hoen PW, de Jonge P. Cognitive/affective and somatic/affective symptoms of depression in patients with heart disease and their association with cardiovascular prognosis: a meta-analysis. Psychol Med 2014;44(13):2689–2703.

16. Delisie VC, Abbey SE, Beck AT, Dobson KS, Dozois DJA, Grace SL, Stewart DE, Ziegelst RC, Thoms BD. The influence of somatic symptoms on Beck Depression Inventory scores in hospitalized post-myocardial infarction patients. Can J Psychiatry 2012;57(12):752–758.

17. Redwine LS, Tsuang M, Rusiewicz A, Pandzic I, Cammarata S, Rutledge T, Hong S, Linke S, Mills PJ. A pilot study exploring the effects of a 12-week tai chi intervention on somatic symptoms of depression in patients with heart failure. J Altern Complement Med 2012;18(8):744–748.

18. Delisie VC, Arturrs E, Abbey SE, Grace SL, Stewart DE, Steele RJ, Ziegelst RC, Thoms BD. Symptom reporting on the Beck Depression Inventory among post-myocardial infarction patients: in-hospital versus follow-up assessments. J Psychosom Res 2012;73(5):356–361.

19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Chamber Quantification Writing Group. American Society of Echocardiography’s Guidelines and Standards Committee, European Association of Echocardiography Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 2005;18(12):1440–1463.

20. Mills PJ, Wilson K, Iqbal N, Iqbal F, Alvarez M, Pung MA, Wachmann K, Rutledge T, Maglione J, Zisook S, Dimsdale JE, Lunde O, Greenberg BH, Maisel A, Raisinghani A, Natarajan L, Jain S, Hufford DJ, Redwine L. Depressive symptoms and spiritual wellbeing in asymptomatic heart failure patients. J Behav Med 2015;38(3):407–415.

21. O’Keeffe ST, Lye M, Donnellan C, Carmichael DN. Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. Heart 1998;80(4):377–382.

22. Beck AT. Depression Inventory. Philadelphia, PA: Center for Cognitive Therapy; 1978.

23. Smyth C. The Pittsburgh Sleep Quality Index (PSQI). Insight 2000;25(3):97–98.

24. Mills PJ, Dimsdale JE, Natarajan L, Ziegler MG, Maisel A, Greenberg BH. Sleep and health-related quality of life in heart failure. Congest Heart Fail 2009;15(5):228–233.

25. Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 1998;45(1):5–13.

26. Sun RR, Lu L, Liu M, Gao Y, Li X, Liu H, Wang J, Zhang PY. Markers and heart disease. Eur Rev Med Pharmacol Sci 2014;18(19):2927–2935.

27. Wang Y, Yang H, Nolan M, Pathan F, Negishi K, Marwick TH. Variations in subclinical left ventricular dysfunction, functional capacity, and clinical outcomes in different heart failure aetiologies. ESC Heart Fail 2018, 5, 343, 354.

28. Mandivvila T, Khalid U. Obesity and cardiovascular disease: a risk factor or a risk marker? Curr Atheroscler Rep 2016;18(5):21.

29. van Dijk SEM, Adriaanse MC, van der Zwaan L, et al. Measurement properties of depression questionnaires in patients with diabetes: a systematic review. Qual Life Res 2018.

30. Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez Roux AV, Lee HB, Lyketsos C. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008;299(23):2751–2759.

31. Hwang B, Moser DK, Pelter MM, Nesbitt TS, Dracup K. Changes in depressive symptoms and mortality in patients with heart failure: effects of cognitive-affective and somatic symptoms. Psychosom Med 2015;77(7):798–807.

32. Wirtz PH, Hong S, Redwine LS, Tafur J, Rutledge T, Ziegler MG, Greenberg B. Mills PJ. Depressive symptoms are associated with soluble P-selectin reactivity to acute exercise in heart failure. Biol Psychiatry 2009;65(9):801–807.

33. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull 2014;140(3):774–815.

34. Cezaratto A, Ferreira SR, Sharma S, Sadeghirad B, Kolahdooz F. Impact of lifestyle interventions on depressive symptoms in individuals at-risk of, or with, type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2016;26(8):649–662.

35. Bernard P, Romain AJ, Caujod R, Chevance G, Carayol M, Gourlan M, Needham Dancauze K, Moulele G. Cognitive behavior therapy combined with exercise for adults with chronic diseases: systematic review and meta-analysis. Health Psychol 2018;37(5):433–450.

36. Lenihan DJ. Progression of heart failure from AHA/ACC stage A to stage B or even C. Can we all agree we should try to prevent this from happening? J Am Coll Cardiol 2012;60(24):2513–2514.

37. Downs CA, Faulkner MS. Toxic stress, inflammation and symptomatology of chronic complications in diabetes. World J Diabetes 2015;6(4):554–565.

38. Hamer M, Endrich R, Poole L. Physical activity, stress reduction, and mood: insight into immunological mechanisms. Methods Mol Biol 2012;934:89–102.

39. Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic
Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res (Hoboken) 2011;63 suppl 11:S454-466.

40. Morys JM, Bellwon J, Adamczyk K, Gruchala M. Depression and anxiety in patients with coronary artery disease, measured by means of self-report measures and clinician-rated instrument. Kardiol Pol 2016; 74(1):53–60.